Product Description
Mechanisms of Action: Immunomodulator
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location:
Company CEO: Severin Schwan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Arthritis, Rheumatoid
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2010-021577-37 |
2010-021577-37 | P2 |
Completed |
Arthritis, Rheumatoid |
2012-09-19 |
2022-03-13 |
Treatments |
|
NCT01225393 |
ALT4864g | P2 |
Completed |
Arthritis, Rheumatoid |
2012-07-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|